BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
358.07
-0.70 (-0.20%)
Oct 2, 2026, 4:00 PM EDT - Market closed
BeOne Medicines AG Stock Forecast
Stock Price Forecast
According to 28 analysts polled by S&P Global, BeOne Medicines AG stock has a consensus rating of "Strong Buy" and an average price target of $432.8. The average 1-year stock price forecast is 20.87% higher than the current stock price, while the lowest is $370 (+3.33%) and the highest is $528 (+47.46%).
Price Target: $432.8 (+20.87%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for BeOne Medicines AG stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 18 | 19 | 19 | 20 | 20 | 20 |
| Buy | 7 | 8 | 8 | 8 | 7 | 7 |
| Hold | 1 | 1 | 1 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 26 | 28 | 28 | 28 | 28 | 28 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| J.P. Morgan | J.P. Morgan | Buy Reiterates $445 | Buy | Reiterates | $445 | +24.28% | Oct 1, 2026 |
| Barclays | Barclays | Buy Maintains $407 → $415 | Buy | Maintains | $407 → $415 | +15.90% | Sep 10, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $450 | Buy | Maintains | $450 | +25.67% | Aug 25, 2026 |
| Wolfe Research | Wolfe Research | Buy Reiterates $340 → $370 | Buy | Reiterates | $340 → $370 | +3.33% | Aug 10, 2026 |
| CMB International Securities | CMB International Securities | Buy Maintains $392 → $442 | Buy | Maintains | $392 → $442 | +23.53% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
6.77B
from 5.34B
Increased by 26.70%
Revenue Next Year
7.76B
from 6.77B
Increased by 14.57%
EPS This Year
0.62
from 0.19
Increased by 224.14%
EPS Next Year
0.87
from 0.62
Increased by 41.92%
EPS and Forward PE are based on non-GAAP adjusted numbers.